3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae037 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Emeline Tabouret und 15 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neurooncologie, Marseille, France. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: PharmaMar, Else Kröner Fresenius Foundation, German Cancer Aid.
Abstract (Originalsprache)
Background
We previously reported that tumor 3D volume growth rate (3DVGR) classification could help in the assessment of drug activity in patients with meningioma using 3 main classes and a total of 5 subclasses: class 1: decrease; 2: stabilization or severe slowdown; 3: progression. The EORTC-BTG-1320 clinical trial was a randomized phase II trial evaluating the efficacy of trabectedin for recurrent WHO 2 or 3 meningioma. Our objective was to evaluate the discriminative value of 3DVGR classification in the EORTC-BTG-1320.
Methods
All patients with at least 1 available MRI before trial inclusion were included. 3D volume was evaluated on consecutive MRI until progression. 2D imaging response was centrally assessed by MRI modified Macdonald criteria. Clinical benefit was defined as neurological or functional status improvement or steroid decrease or discontinuation.
Results
Sixteen patients with a median age of 58.5 years were included. Best 3DVGR classes were: 1, 2A, 3A, and 3B in 2 (16.7%), 4 (33.3%), 2 (16.7%), and 4 (33.3%) patients, respectively. All patients with progression-free survival longer than 6 months had best 3DVGR class 1 or 2. 3DVGR classes 1 and 2 (combined) had a median overall survival of 34.7 months versus 7.2 months for class 3 (P = .061). All class 1 patients (2/2), 75% of class 2 patients (3/4), and only 10% of class 3 patients (1/10) had clinical benefit.
Conclusions
Tumor 3DVGR classification may be helpful to identify early signals of treatment activity in meningioma clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neurooncologie, Marseille, France.
- Faculty of Medicine and Dentistry, Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Danube Private University, Krems, Austria.
- Aix-Marseille Univ, APHM, CHU Timone, Service de Neuro-chirurgie, Marseille, France.
- Department of Neuro-Oncology, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
- Department of Neurosurgery, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
ORCID-Profile: Emeline Tabouret, Emilie Le Rhun, Riccardo Soffietti, Giuseppe Lombardi, Petter Brandal, Martin Bendszus, Michael Weller, Felix Sahm, Wolfgang Wick, Matthias Preusser
Förderung
- PharmaMar
- Else Kröner Fresenius Foundation
- German Cancer Aid
Zitieren
APA
Tabouret, E., Furtner, J., Graillon, T., Silvani, A., Le Rhun, E., Soffietti, R., Lombardi, G., Sepúlveda-Sánchez, J. M., Brandal, P., Bendszus, M., Golfinopoulos, V., Gorlia, T., Weller, M., Sahm, F., Wick, W., & Preusser, M. (2024). 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae037
Vancouver
Tabouret E, Furtner J, Graillon T, Silvani A, Le Rhun E, Soffietti R, et al. 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae037
BibTeX
@article{Tabouret2024,
author = {Tabouret, Emeline and Furtner, Julia and Graillon, Thomas and Silvani, Antonio and Le Rhun, Emilie and Soffietti, Riccardo and Lombardi, Giuseppe and Sepúlveda-Sánchez, Juan Manuel and Brandal, Petter and Bendszus, Martin and Golfinopoulos, Vassilis and Gorlia, Thierry and Weller, Michael and Sahm, Felix and Wick, Wolfgang and Preusser, Matthias},
title = {3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae037}
}
EUVIMED